NEW YORK ( TheStreet) -- CHANGE IN RATINGSAmgen ( AMGN) rated new Buy at Stifel Nicolaus. $68 price target. Company has the only major new product among its peers. Celanese ( CE) upgraded at Citigroup from Hold to Buy. $35 price target. Company is growing in China, which should also help keep costs down. Celgene ( CELG) rated new Buy at Stifel Nicolaus. $71 price target. Company has superior growth prospects. Gilead Sciences ( GILD) rated new Hold at Stifel Nicolaus. Valuation call, as the company is facing patent expirations. Idexx Laboratories ( IDXX) rated new Market Perform at Leerink. Stock is already pricing in the company's organic growth potential. Skilled Healthcare Group ( SKH) upgraded at Credit Suisse to Neutral from Underperform as the company agreed to a $50 million settlement in the Lavender case. The settlement was significantly lower than the Street's expectation, Credit Suisse said. Price target increased to $5 from $2. Teva Pharmaceutical ( TEVA) upgraded at Oppenheimer from Perform to Outperform, Oppenheimer said. $65 price target. Effexor XR launch was strong and the company should post better earnings in the second half of 2010. Tellabs ( TLAB) downgraded at Soleil from Buy to Hold. $8 price target. Estimates also cut, as the company is losing market share at Soleil. Valspar ( VAL) was downgraded at Citigroup from Buy to Hold. $32 price target. Paint sales tailed off toward the end of summer, as the housing market soured.